The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.

Global cellular response to chemotherapy-induced apoptosis. Elife (2013) 1.19

Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget (2013) 1.02

Heat shock proteins in multiple myeloma. Oncotarget (2014) 0.95

HSF1: Guardian of Proteostasis in Cancer. Trends Cell Biol (2015) 0.94

Novel therapeutic strategies for multiple myeloma. Exp Hematol (2015) 0.91

The 26S proteasome is a multifaceted target for anti-cancer therapies. Oncotarget (2015) 0.88

Mechanisms of Hsp90 regulation. Biochem J (2016) 0.84

Higher heat shock factor 1 expression in tumor stroma predicts poor prognosis in esophageal squamous cell carcinoma patients. J Transl Med (2015) 0.79

The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors. J Proteome Res (2013) 0.79

When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. Mol Cancer Res (2015) 0.79

Misfolded proteins: from little villains to little helpers in the fight against cancer. Front Oncol (2015) 0.78

Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia. Oncotarget (2015) 0.78

Pleiotropic role of HSF1 in neoplastic transformation. Curr Cancer Drug Targets (2014) 0.78

Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis. Genome Med (2014) 0.77

The heat-shock, or HSF1-mediated proteotoxic stress, response in cancer: from proteomic stability to oncogenesis. Philos Trans R Soc Lond B Biol Sci (2018) 0.76

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis. J Hematol Oncol (2015) 0.76

The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. PLoS One (2016) 0.75

Doxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-IIR-dependent cardiomyocyte death. Cell Death Dis (2016) 0.75

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget (2016) 0.75

Regulatory Mechanisms of Hsp90. Biochem Mol Biol J (2017) 0.75

[Predictive molecular pathological stratification of hematological neoplasms]. Pathologe (2016) 0.75

A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress. BMC Cancer (2017) 0.75

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol (2011) 5.30

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood (2007) 5.18

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 5.10

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol (2006) 4.70

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol (2013) 4.50

Shifting foci of hematopoiesis during reconstitution from single stem cells. Proc Natl Acad Sci U S A (2003) 4.41

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol (2009) 3.91

Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89

Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol (2008) 3.44

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood (2012) 3.38

Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood (2006) 3.33

Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood (2007) 3.27

Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med (2014) 3.12

Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J (2006) 3.07

A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol (2013) 2.98

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood (2011) 2.87

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood (2006) 2.83

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood (2010) 2.82

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol (2008) 2.77

Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol (2006) 2.28

BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med (2012) 2.25

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis (2011) 2.19

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood (2012) 2.19

Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med (2010) 2.17

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13

Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood (2011) 2.12

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol (2010) 2.09

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol (2007) 2.09

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood (2009) 2.09

Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis (2004) 1.98

Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica (2010) 1.91

In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood (2006) 1.89

Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation. Transplantation (2005) 1.82

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood (2008) 1.69

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood (2005) 1.69

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood (2008) 1.67

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood (2011) 1.65

Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol (2014) 1.61

High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol (2013) 1.60

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood (2009) 1.59

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica (2004) 1.54

Signalling and survival pathways in multiple myeloma. Eur J Cancer (2006) 1.52

Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood (2010) 1.52

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52

Surface display of Gaussia princeps luciferase allows sensitive fungal pathogen detection during cutaneous aspergillosis. Virulence (2012) 1.50

Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion (2010) 1.49

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood (2010) 1.49

Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol (2005) 1.49

Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49

Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev (2010) 1.48

Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood (2002) 1.47

Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol (2012) 1.46

STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood (2006) 1.44

Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells. Blood (2012) 1.44

Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood (2004) 1.43

How to treat multiple myeloma - a representative multicentre treatment survey. Onkologie (2010) 1.43

Aspergillus fumigatus antigens activate innate immune cells via toll-like receptors 2 and 4. Br J Haematol (2004) 1.42

Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med (2006) 1.41

Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood (2003) 1.39

Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α+ type. J Immunol (2011) 1.39

Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series. Leuk Lymphoma (2009) 1.38

Automated extraction of genomic DNA from medically important yeast species and filamentous fungi by using the MagNA Pure LC system. J Clin Microbiol (2002) 1.38

High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol (2002) 1.34

T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol (2003) 1.33

Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood (2006) 1.31

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood (2013) 1.30

Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol (2008) 1.29

IMWG consensus on maintenance therapy in multiple myeloma. Blood (2012) 1.29

Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood (2005) 1.28

A tumor-suppressor function for NFATc3 in T-cell lymphomagenesis by murine leukemia virus. Blood (2005) 1.27

Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood (2004) 1.25

Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells (2009) 1.25

Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood (2005) 1.24

Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica (2008) 1.24

Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood (2003) 1.22

Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol (2004) 1.20

Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis (2012) 1.20

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood (2010) 1.19

Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation (2003) 1.18

Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood (2011) 1.18